Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Expression of XPG protein in human normal and tumor tissues.
Aracil M, Dauffenbach LM, Diez MM, Richeh R, Moneo V, Leal JF, Fernández LF, Kerfoot CA, Galmarini CM. Aracil M, et al. Int J Clin Exp Pathol. 2013;6(2):199-211. Epub 2013 Jan 15. Int J Clin Exp Pathol. 2013. PMID: 23330005 Free PMC article.
The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, del Carmen García-Macías M, Sevillano V, Alonso D, Pascual-Pasto G, San-Segundo L, Vila-Ubach M, Rodrigues T, Fraile S, Teodosio C, Mayo-Iscar A, Aracil M, Galmarini CM, Tirado OM, Mora J, de Álava E. Ordóñez JL, et al. Among authors: aracil m. Oncotarget. 2015 Aug 7;6(22):18875-90. doi: 10.18632/oncotarget.4303. Oncotarget. 2015. PMID: 26056084 Free PMC article.
Levels of p27(kip1) determine Aplidin sensitivity.
Moneo V, Serelde BG, Leal JF, Blanco-Aparicio C, Diaz-Uriarte R, Aracil M, Tercero JC, Jimeno J, Carnero A. Moneo V, et al. Among authors: aracil m. Mol Cancer Ther. 2007 Apr;6(4):1310-6. doi: 10.1158/1535-7163.MCT-06-0729. Mol Cancer Ther. 2007. PMID: 17431109
Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ, Lorusso D, Italiano A, Kaye SB, Aracil M, Tanović A, D'Incalci M. Monk BJ, et al. Among authors: aracil m. Cancer Treat Rev. 2016 Nov;50:175-182. doi: 10.1016/j.ctrv.2016.09.009. Epub 2016 Sep 15. Cancer Treat Rev. 2016. PMID: 27710871 Review.
Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, García-Macías MDC, Sevillano V, Alonso D, Pascual-Pasto G, San-Segundo L, Vila-Ubach M, Rodrigues T, Fraile S, Teodosio C, Mayo-Iscar A, Aracil M, Galmarini CM, Tirado OM, Mora J, de Álava E. Ordóñez JL, et al. Among authors: aracil m. Oncotarget. 2017 Jun 27;8(26):43592. doi: 10.18632/oncotarget.18610. Oncotarget. 2017. PMID: 28672777 Free PMC article. No abstract available.
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).
Gaillard S, Oaknin A, Ray-Coquard I, Vergote I, Scambia G, Colombo N, Fernandez C, Alfaro V, Kahatt C, Nieto A, Zeaiter A, Aracil M, Vidal L, Pardo-Burdalo B, Papai Z, Kristeleit R, O'Malley DM, Benjamin I, Pautier P, Lorusso D. Gaillard S, et al. Among authors: aracil m. Gynecol Oncol. 2021 Nov;163(2):237-245. doi: 10.1016/j.ygyno.2021.08.032. Epub 2021 Sep 11. Gynecol Oncol. 2021. PMID: 34521554 Clinical Trial.
47 results